Section Arrow
ERAS.NASDAQ
- Erasca
Quotes are at least 15-min delayed:2026/08/31 09:15 EDT
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
18.03 
1-M High
20.4 
Volume 
-- 
Bid
17.9
Ask
--
Day Low
-- 
Open
-- 
1-M Low
16.88 
Market Cap 
6.31B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 18.12 
20-SMA 18.2 
50-SMA 18.1 
52-W High 24.28 
52-W Low 1.3301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.95/-0.58
Enterprise Value
6.35B
Balance Sheet
Book Value Per Share
1.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
ZVRAZevra Therapeutics------12.44PE
ZURAZura Bio Limited-------- 
ZNTLZentalis Pharmaceuticals-------- 
ZLABZai Lab Limited-------- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Itspipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.